CytoSorbents Corporation (CTSO)

Over the past six months, CytoSorbents' stock price has fluctuated between $0.60 and $1.61. In August 2025, the company reported a revenue increase and announced an appeal hearing with the FDA, leading to positive stock changes. In September 2025, CytoSorbents updated on DrugSorb-ATR, indicating plans to file a new De Novo application. In November 2025, the company reported its third-quarter financial results, with revenue increasing and EPS exceeding expectations. In December 2025, CytoSorbents participated in a virtual fireside chat, and D. Boral Capital maintained a Buy recommendation. In January 2026, the company reported preliminary fourth-quarter and full-year results, with a De Novo Pre-Submission Meeting with the FDA scheduled, leading to stock increases and an increased price target from D. Boral Capital. The share price as of January 22, 2026, represented a decline of 34.35% from January 23, 2025.

Demand for CytoSorbents' products in critical care is generally inelastic. The company benefits from a solid, recurring revenue base in the European Union's critical care market, suggesting that demand is not significantly impacted by seasonal fluctuations.

CytoSorbents Corporation is a medical device company specializing in blood purification technologies for life-threatening conditions, operating within the Medical sector, specifically in the Medical Equipment and Products industry. The company's blood purification technologies utilize biocompatible, highly porous polymer beads to remove toxic substances from blood and other bodily fluids. Major products include CytoSorb, a cytokine filter for critically ill patients, and DrugSorb-ATR, an investigational product for removing blood-thinning drugs.

CytoSorbents has a significant international presence, with CytoSorb approved in the EU and distributed in over 70 countries. Germany is a major market. The U.S. market strategy focuses on establishing infrastructure and marketing leadership for DrugSorb-ATR, pending FDA approval.

CytoSorbents' brand reputation is closely tied to its clinical trial progress and financial performance. The company has a consensus rating of "Hold" from analysts, with an average rating score of 2.00. The U.S. clinical trials for DrugSorb-ATR are critical, with the U.S. market strategy contingent on successful outcomes and FDA approval expected in mid-2026.

CytoSorbents Corporation's ownership is distributed among institutional investors, individual insiders, and the general public. Approximately 20.68% to 23.83% of the company's stock is owned by Institutional Investors, 5.93% by Insiders, and a significant portion (3.15% to 70.24%) by Public Companies and Individual Investors. Major institutional owners and shareholders include Avenir Corp, Simplex Trading, Llc, Vanguard Group Inc, Skylands Capital, LLC, Neuberger Berman Group LLC, CM Management, LLC, Jpmorgan Chase & Co, IMC-Chicago, LLC, BlackRock, Inc., CIBC Private Wealth Advisors, Inc., State Street Global Advisors, Inc., and Raymond James Financial, Inc.